Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).

Trial Details

NCT ID
NCT06425926
Phase
PHASE1 / PHASE2
Sponsor
Georgiamune Inc
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • GIM-531
  • Anti-PD-1 monoclonal antibody
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Bakersfield, California, United States|35.37329,-119.01871
  • Fullerton, California, United States|33.87029,-117.92534
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Written informed consent
  • Cytologically or histologically confirmed locally advanced or metastatic solid tumor that has progressed on standard therapy or for which no standa…
  • Have not received an experimental drug within 4 weeks or 5 half-lives (whichever is shorter) of study drug treatment or already be enrolled in a cl…
  • ECOG performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →